# OnCo record high-grade-serous-ovarian-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/high-grade-serous-ovarian-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "high-grade-serous-ovarian-cancer" ;
  schema:name "High-grade serous ovarian cancer"@en ;
  schema:alternateName "HGSOC"@en, "High-grade serous carcinoma of the ovary, fallopian tube and peritoneum"@en ;
  schema:description "High-grade serous cancer is the common, aggressive form of ovarian cancer, now known to start in the fallopian tube. It is treated with surgery and platinum chemotherapy, and maintenance PARP inhibitors have changed its course for the half of patients whose tumours cannot repair DNA properly."@en ;
  schema:url <https://onco.cc/cancers/high-grade-serous-ovarian-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Ovarian_cancer> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/platinum-sensitive-ovarian-cancer/>, <https://onco.cc/cancers/platinum-resistant-ovarian-cancer/>, <https://onco.cc/cancers/low-grade-serous-ovarian-cancer/>, <https://onco.cc/cancers/clear-cell-ovarian-cancer/> ;
  onco:trials <https://onco.cc/trials/soraya/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-solo-1-nejm-2018/>, <https://onco.cc/key-papers/paper-paola-1-nejm-2019/>, <https://onco.cc/key-papers/paper-mirasol-nejm-2023/>, <https://onco.cc/key-papers/paper-tcga-ovarian-nature-2011/> ;
  onco:pipeline <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/targets/folr1/> ;
  onco:standardOfCare <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/technologies/hipec/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/trials/solo-1/>, <https://onco.cc/trials/prima/>, <https://onco.cc/trials/paola-1/>, <https://onco.cc/terms/hrd/>, <https://onco.cc/targets/brca/>, <https://onco.cc/trials/desktop-iii/>, <https://onco.cc/drugs/rucaparib/>, <https://onco.cc/drugs/niraparib/>, <https://onco.cc/drugs/mirvetuximab-soravtansine/>, <https://onco.cc/targets/folr1/>, <https://onco.cc/drugs/relacorilant/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/targets/brca/>, <https://onco.cc/technologies/risk-reducing-salpingectomy/> .